ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.36M | 7.71M | 8.11M | 9.99M | 11.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.14M | 9.63M | 10.26M | 12.66M | 14.42M |
| Operating Income | -9.14M | -9.63M | -10.26M | -12.66M | -14.42M |
| Income Before Tax | -9.41M | -21.92M | -22.42M | -105.99M | -107.75M |
| Income Tax Expenses | 6.70K | -586.40K | -586.90K | -8.41M | -9.46M |
| Earnings from Continuing Operations | -9.41 | -21.33 | -21.83 | -97.58 | -98.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.41M | -21.33M | -21.83M | -97.58M | -98.30M |
| EBIT | -9.14M | -9.63M | -10.26M | -12.66M | -14.42M |
| EBITDA | -9.13M | -9.62M | -10.25M | -12.64M | -14.41M |
| EPS Basic | -10.99 | -72.35 | -100.10 | -1.79K | -1.92K |
| Normalized Basic EPS | -6.86 | -11.58 | -28.72 | -89.75 | -196.93 |
| EPS Diluted | -10.99 | -72.35 | -100.10 | -1.79K | -1.92K |
| Normalized Diluted EPS | -6.86 | -11.58 | -28.72 | -89.75 | -196.93 |
| Average Basic Shares Outstanding | 4.44M | 2.66M | 1.77M | 986.80K | 389.30K |
| Average Diluted Shares Outstanding | 4.44M | 2.66M | 1.77M | 986.80K | 389.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |